{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:40:36Z","timestamp":1774453236703,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.mcna.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T17:58:07Z","timestamp":1543859887000},"page":"325-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System"],"prefix":"10.1016","volume":"103","author":[{"given":"Kristin M.","family":"Galetta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamik","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mcna.2018.10.004_bib1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology","volume":"9","author":"Koch-Henriksen","year":"2010","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2018.10.004_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0036-1579693","article-title":"Epidemiology of multiple sclerosis: from risk factors to prevention-an update","volume":"36","author":"Ascherio","year":"2016","journal-title":"Semin Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2018.10.004_bib3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","article-title":"Role of the innate and adaptive immune responses in the course of multiple sclerosis","volume":"14","author":"Hemmer","year":"2015","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2018.10.004_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mcna.2018.10.004_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.msard.2017.08.016","article-title":"Radiologically isolated syndrome and multiple sclerosis","volume":"17","author":"Yamout","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.mcna.2018.10.004_bib6","article-title":"Corticosteroids for the long-term treatment in multiple sclerosis","author":"Ciccone","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"9997","key":"10.1016\/j.mcna.2018.10.004_bib7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mcna.2018.10.004_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2018.10.004_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.mcna.2018.10.004_bib10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 microg or 500 microg interferon beta-1b versus 20\u00a0mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O\u2019Connor","year":"2009","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.mcna.2018.10.004_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2018.10.004_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A\u00a0randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2018.10.004_bib13","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1212\/NXI.0000000000000167","article-title":"Effect of vitamin D on MS activity by disease-modifying therapy class","volume":"2","author":"Rotstein","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.mcna.2018.10.004_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mcna.2018.10.004_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.mcna.2018.10.004_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcna.2018.10.004_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"4","key":"10.1016\/j.mcna.2018.10.004_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.mcna.2018.10.004_bib19","first-page":"2013","article-title":"Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome","volume":"262","author":"Koelman","year":"2015","journal-title":"J\u00a0Neurol"},{"issue":"16 Suppl 2","key":"10.1016\/j.mcna.2018.10.004_bib20","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1212\/01.wnl.0000259404.51352.7f","article-title":"Acute disseminated encephalomyelitis","volume":"68","author":"Tenembaum","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mcna.2018.10.004_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11940-012-0170-0","article-title":"Treatment of acute disseminated encephalomyelitis","volume":"14","author":"Pohl","year":"2012","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2018.10.004_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A\u00a0clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2018.10.004_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1474-4422(08)70060-7","article-title":"Paraneoplastic syndromes of the CNS","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2018.10.004_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/jnnp.2008.159483","article-title":"Cerebrospinal fluid study in paraneoplastic syndromes","volume":"81","author":"Psimaras","year":"2010","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcna.2018.10.004_bib25","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","author":"Dalmau","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mcna.2018.10.004_bib26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.mcna.2018.10.004_bib27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jocn.2013.07.017","article-title":"Autoimmune encephalitis: recent updates and emerging challenges","volume":"21","author":"Ramanathan","year":"2014","journal-title":"J\u00a0Clin Neurosci"},{"issue":"2","key":"10.1016\/j.mcna.2018.10.004_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.mcna.2018.10.004_bib29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/WCO.0000000000000444","article-title":"Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies)","volume":"30","author":"Bastiaansen","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"10.1016\/j.mcna.2018.10.004_bib30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.0000000000003009","article-title":"Anti-LGI1\u2013associated cognitive impairment","volume":"87","author":"Ari\u00f1o","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mcna.2018.10.004_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/WCO.0b013e3283608459","article-title":"Neurosarcoidosis: diagnostic approaches and therapeutic strategies","volume":"26","author":"Segal","year":"2013","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.mcna.2018.10.004_bib32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/B978-0-7020-4086-3.00021-7","article-title":"Neurologic manifestations of sarcoidosis","volume":"119","author":"Krumholz","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2018.10.004_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis\u2014diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM"},{"key":"10.1016\/j.mcna.2018.10.004_bib34","article-title":"Discriminating long myelitis of neuromyelitis optica from sarcoidosis","author":"Flanagan","year":"2015","journal-title":"Ann Neurol"},{"issue":"20","key":"10.1016\/j.mcna.2018.10.004_bib35","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518301263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518301263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T08:16:21Z","timestamp":1548749781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712518301263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0025712518301263"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2018.10.004","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}